RxDoctor Payments Data

Bianca Barcelo, MD

Neurology · Chicago, ILNPI 1154779718

Payments from drug & device makers

$2,410in general payments, 2019–2025

Across 103 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$150
  • Merck$149
  • Akcea Therapeutics, Inc.$146
  • Lundbeck LLC$145
  • Portola Pharmaceuticals, LLC$144
  • plus $494 from 10 others

What the payments were for

  • Food & beverage$2,410100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,410 in reported general payments places this provider in the 60th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$41,889
Medicare patients
74
Services billed
4,636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant52$76,222
QuliptaAtogepant53$64,896
Nurtec OdtRimegepant Sulfate27$55,049
Emgality PenGalcanezumab-Gnlm48$41,744
Naratriptan Hcl21$1,175
Gabapentin71$989
RizatriptanRizatriptan Benzoate21$343
Topiramate18$284
Cyclobenzaprine Hcl11$181
Pregabalin13$170
Venlafaxine Hcl ErVenlafaxine Hcl11$164
Amitriptyline Hcl16$108
Tizanidine Hcl11$43
Propranolol Hcl14$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,181$141,117105 claims
PfizerNurtec Odt$73$55,04927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 790 neurology providers in Illinois.

Other neurology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →